Turning tumors into all-in-one immunotherapy bioreactors.
Our Symphony™ platform turns tumors into all-in-one immunotherapy bioreactors. One injection. Ten-plus staged, secreted payloads. A non-replicating gene therapy engineered to solve — at once — every mechanism that keeps cold tumors cold.
Turning tumors into all-in-one immunotherapy bioreactors.
Cold tumors combine immunosuppressive cells, antigen suppression, checkpoint overexpression, T-cell neutralization and immune-cell exclusion behind dense stromal barriers — beyond what any single agent or tolerated systemic combination can overcome.
Intratumoral multimodal therapy is the answer, yet first-generation modalities encounter distinct biological and operational barriers. Intratumoral cryolysis-based multi-payload therapy has effectively been validated as an approach, but its clinical implementation involves higher procedural and manufacturing complexity, including device-based delivery and multi-agent regimens. Conversely, armed oncolytic viruses consolidate multi-pathway delivery into a single therapeutic agent; however, premature viral-mediated oncolysis can inherently restrict the window for sustained, robust payload expression.
Over two years we made the discoveries that resolve every one of these limitations — engineered secretion, staged logic-gated promoters, secretable lysis modules, and superpotent proteins — packaged into a single non-replicating HD-Ad vector. Wholly owned.
Cold tumors are protected by many concurrent mechanisms.
Systemic multi-agent immunotherapy cannot safely cover this network. FIG delivers a once-injected gene therapy designed to address all of these mechanisms at once — locally, from inside the tumor.
Suppressive immune cells
- M2 macrophages
- MDSCs
- T-regulatory cells
- Cancer-associated fibroblasts
Suppressive signaling & immune masking
- TGF-β, IL-10, VEGF
- Immunosuppressive chemokines
- PD-L1 overexpression
- MHC-I suppression
Physical & metabolic barriers
- Dendritic-cell desert
- Dense extracellular matrix
- Hypoxia
- Acidosis
Intratumoral multimodal immunotherapy — but first-generation approaches hit ceilings.
Only local, multimodal therapy can address every mechanism at once without systemic toxicity. The rise of intratumoral immunotherapy — armed oncolytic viruses, multi-agent device-delivered regimens, intratumoral mRNA, prodrug adenovirus — validates the thesis. Each also reveals where its format falls short.
Comparison reflects general modality classes; individual programs vary.
Non-replicating viruses should solve this. Tumors don't secrete.
A non-replicating vector could deliver a full multimodal payload without destroying its own producer cell. But tumors are intrinsically poor secretors of therapeutic proteins — the field-wide reason non-replicating intratumoral gene therapy has never lived up to its promise.
We spent two years obsessing over each of these barriers — engineered secretion, staged logic-gated promoters, secretable lysis modules, and superpotent proteins — and built the Symphony™ platform on multiple independent layers of wholly owned IP.
We engineered tumors into high-output secretors.
Tumor cells are intrinsically poor secretors of immunotherapeutic payloads — the historical bottleneck limiting intratumoral gene therapy. Holding the promoter constant, we tested a library of rationally designed non-native signal peptides. One resulted in massive secretion — over 700-fold greater than native — an effect observed only in tumor cells.
This foundational unlock makes multimodal intratumoral gene immunotherapy feasible for the first time.
See the Symphony™ platformHolding CMV promoter constant. FIG signal peptide 3 unlocked >700× secretion vs native, in tumor cells only.
SP = signal peptide
Prostate first — a large, underserved market fit to the platform.
A $100B+ solid-tumor immuno-oncology TAM, with mCRPC alone projected to grow from $21B to $92B by 2034. ~70,000 U.S. high-risk localized cases per year, more than half recurring despite surgery or radiation — and a needle-accessible tumor architected around exactly the immune barriers Symphony™ is built to solve.
See the pipeline